

Index

A

Acetylglucosaminyltransferase, 98
Adventitious agent safety, 76
Affinity chromatography, 25
Alemtuzumab, 99
Amidation, 3, 96
Amino acid residues, modifications, 110
Antibody(ies), 1, 24, 28–31, 42, 72, 94, 144, 162
 aggregates, 100
 antidrug (ADA), 77, 94, 123, 135
 anti-FVIII, 123
 monoclonal, 1, 24, 28–31, 42, 72, 94, 144, 162
Antibody-dependent cellular cytotoxicity (ADCC), 95
Antibody-dependent cellular phagocytosis (ADCP), 95
Antidrug antibodies (ADA), 77, 94, 123, 135
Antigens, 80–86, 95, 125, 137, 141–148, 153
 binding, 95–101
 human leukocyte (HLA), 126
 presentation assay, 153, 154

B

BAY 86-6150, 124
Bioassays, 84, 86, 102, 106
Biologics, 2, 16, 30, 69, 75, 84, 104, 109
Bioreactors, 1–19, 30, 46–51, 59, 79, 96
 sterility, 1
Biosimilars, 41, 42, 57, 59, 60

C

Carboxylation, 3, 89
Cell banks/banking, 9–13, 28, 76
Cell cultures, 3, 13, 49, 74, 84, 88, 91, 106–108, 111
 mammalian, 49
 media, 4, 9, 12, 15, 25, 30
 scale up, 1
Cell harvesting, 1, 14, 19, 20
Cell lines, screening, 1
Centrifugation, 1, 19, 20, 22, 90
 continuous, 1, 24
Cetuximab, 98
Chemometrics, 59
Chinese hamster ovary cell line, 1, 4
Chromatography, 1, 3, 52, 55, 59, 111
 affinity, 24, 25, 91
 anion exchange, 56
 HPLC, 57, 105
 ion exchange, 1, 26
 membrane, 55
 multimodal, 26
 process, 51, 52
 purification, 74
 sigma factor, 1
 size-exclusion, 57, 90, 111
 ultra-performance liquid (UPLC), 110
Clone selection, 7, 10, 50
Codons, synonymous, 161
 usage, 161
Complement-dependent cytotoxicity (CDC), 95

Cost modelling, 1, 31
 Cost of goods, 1, 23
 CRISPR-Cas9 system, 5
 Critical process parameters (CPP), 45, 47, 60
 Critical quality attributes (CQA), 42, 45
 Cytotoxic T-lymphocyte-associated protein
 4 (CTLA-4), 126

D

Deamidation, 57, 58, 96, 110
 Depth filtration, 1, 20
 Diafiltration (DF), 25, 28, 53
 Dihydrofolate reductase (DHFR), 5
 Disc stack centrifuge, 1
 Downstream filtration, 20
 Downstream processing, 41, 46, 51–56, 100
 DUXB11, 5
 Dynamic binding capacity (DBC), 27

E

Economies of scale, 1, 29
 Efficacy, 41, 57
 ELISA, 91
 End of production cell banks (EPCB), 12
 Enzymatic assays, 106
 Enzyme(s), 4, 42, 77, 89, 91, 95, 98, 104–110
 therapies, 4
 Enzyme replacement therapy (ERT), 110
 Epratuzumab, 100
Escherichia coli, 3, 48, 51, 163, 166–169

F

Factor IX, 88, 125
 Factor VII analog, 123
 Factor VIII, 25, 88, 125
 Filter sizing, harvest operations, 22
 FIX-bypassing agents, 127
 Fluorescence-activated cell sorter (FACS), 8
 Frameshifting, 169
 FVIIa, 123
 recombinant (rFVIIa), 127
 FVIII-bypassing agents, 127

G

Gene redesign, 161
 Genetic stability, 1
 Gene transfection, 5
 Glutamine synthetase (GS), 6
 Glycosylation, 3, 47

H

Hemophilia, 88, 123, 125
 immune responses, 125
 Hemostasis, 86
 High-throughput process development
 (HTPD), 55
 Host cell protein (HCP), 1, 23
 Human embryonic kidney cell line
 (HEK-293), 4
 Hydrophobic interaction chromatography
 (HIC), 26
 Hydroxylation, 3

I

ICH Q1A-Q1E, 73
 ICH Q2, 73
 ICH Q5A, 13, 76
 ICH Q5B, 10
 ICH Q5D, 10, 11, 13
 ICH Q5E, 73, 79
 ICH Q6B, 73, 75, 77, 91
 ICH Q8(R2), 23, 73
 ICH Q9-11, 72
 Immunization, 80, 83, 130
 Immunogenicity, 4, 77, 123, 130
 Immunoglobulins, 83, 84, 126, 152
 IgG, 80, 126
 plasma-derived, 80
 Impurities, product-related, 99
 Inhibitors, 123
 Inoculum train, 13
 Insulin, 3
 Interleukin (IL)-10, 126
 Ion exchange chromatography, 1, 26

L

Limit of in vitro cell age cell banks
 (LIVCACB), 12

M

Major histocompatibility complex class II
 (MHC-II), 126
 Matrix attachment regions (MARS), 6
 Medium optimization, 1
 Meganucleases, 5
 Membrane chromatography, 55
 Methionine sulfoximine, 6
 Methotrexate, 6
 Microfiltration (MF), 53
 Mistranslation, 161, 169

- Mono-mannose-6-phosphate (M6P), 110
Multimodal chromatography, 26
Multivariate data analysis (MVDA), 49, 59, 60
- N**
Nanofiltration (NF), 53
N-Glycolylneuraminic acid (NGNA), 4
- O**
Open reading frames (ORF), 165
ORFeomes, 166, 167
- P**
PEGylation, 108
PER.C6, 4
Phenotypic stability, 1
Polypeptide tags, 109
Posttranslational modifications (PTMs), 3, 5,
74, 89, 95, 126
Potency, 75, 105
Prediction, 21, 28, 48, 123, 130, 141
Process analytical technology (PAT), 41, 43
Process chromatography, 52
Process control, 44, 45, 50, 53, 79, 85
Process economics, 1, 24, 29
Process validation (PV), 45, 61, 72, 79
Product-related impurities, 99
Proline, amidation, 96
Proteases, 88, 99, 111, 128
inhibitors, 87
Protein A, 25
Proteins, expression, 1
folding, 161
recombinant, 162
refolding, 51
synthesis, 161
therapeutics, 3, 69
Purification, 1, 10, 14, 19, 23, 51, 71, 74, 85, 104
Purity, 3, 23, 57, 74, 105
Pyroglutamic acid, 96
- Q**
Quality by Design (QbD), 41
Quality target product profile (QTPP), 42, 45, 72
- R**
Rare codon clusters, 167
Rare synonymous codons, 161
Receptor/ligand binding affinity assays, 107
- Recombinant proteins, expression systems, 162
therapeutics, 161
Regulatory frameworks, 72
Ribosome binding site (RBS), 166
RNA, mRNA, 161
stability, 168
turnover, 161
Run rate, 1, 30
- S**
Safety, 41, 57, 76
testing, 13
Serine protease, 88, 128
Sialylation, 108
Sigma factor chromatography, 1
Signal recognition particle (SRP), 166
Single-cell progeny, 7
Stability, 78
phenotypic/genotypic, 10
Staphylococcal Protein A (SpA), 25
Sterility, 1, 16, 19, 72, 78, 86
Sterility assurance level (SAL), 16
Sulfation, 3
Synonymous codons, 161, 164
- T**
Talens, 5
Tangential flow filtration (TFF), 20
T-cell epitopes, 123
Therapeutic proteins, 69, 161
Tissue factor (TF), 127
Transient expression, 6
Tumor necrosis factor- α (TNF α), 126
- U**
Ubiquitous chromatin opening elements
(UCOE), 6
Ultrafiltration (UF), 53
/diafiltration (UF/DF), 28
Upstream processes/processing, 8, 10, 41, 47,
50, 86, 100, 110
- V**
Vaccinations, 80, 83
Vaccines, design, 143
influenza, 15
Vatreptacog alfa, 123, 128
immunogenicity, 141, 152
Viral clearance, 1, 24, 28, 31, 54, 56, 76
Viral filtration, 51, 54

Viral safety, 28, 76, 83, 86, 91

Viruses, 1, 16, 86

 inactivation/deactivation, 4, 71, 77, 85

W

Warfarin (coumadin), 71

Y

Yeastolates, 46

Z

Zinc finger nucleases, 5